Abstract

Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.

This guidance replaces NICE technology appraisal guidance on paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (TA91) and trabectedin for the treatment of relapsed ovarian cancer (TA222).

Guidance development process

How we develop NICE technology appraisal guidance

Next review date: April 2019